These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1199 related items for PubMed ID: 18179782

  • 21. Increased urinary aquaporin-2 excretion in response to furosemide in patients with chronic heart failure.
    Starklint J, Bech JN, Nyvad O, Jensen P, Pedersen EB.
    Scand J Clin Lab Invest; 2006; 66(1):55-66. PubMed ID: 16464787
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Angiotensin II AT1 receptor antagonism prevents detrimental renal actions of acute diuretic therapy in human heart failure.
    Chen HH, Redfield MM, Nordstrom LJ, Cataliotti A, Burnett JC.
    Am J Physiol Renal Physiol; 2003 May; 284(5):F1115-9. PubMed ID: 12676739
    [Abstract] [Full Text] [Related]

  • 28. Short-term effects of low-dose tolvaptan on hemodynamic parameters in patients with chronic heart failure.
    Watanabe K, Dohi K, Sugimoto T, Yamada T, Sato Y, Ichikawa K, Sugiura E, Kumagai N, Nakamori S, Nakajima H, Hoshino K, Machida H, Okamoto S, Onishi K, Nakamura M, Nobori T, Ito M.
    J Cardiol; 2012 Dec; 60(6):462-9. PubMed ID: 23068288
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Response Prediction and Influence of Tolvaptan in Chronic Heart Failure Patients Considering the Interaction of the Renin-Angiotensin-Aldosterone System and Arginine Vasopressin.
    Kadota M, Ise T, Yagi S, Iwase T, Akaike M, Ueno R, Kawabata Y, Hara T, Ogasawara K, Bando M, Bando S, Matsuura T, Yamaguchi K, Yamada H, Soeki T, Wakatsuki T, Sata M.
    Int Heart J; 2016 Jul 27; 57(4):461-5. PubMed ID: 27357439
    [Abstract] [Full Text] [Related]

  • 33. Safety of add-on tolvaptan in patients with furosemide-resistant congestive heart failure complicated by advanced chronic kidney disease: a sub-analysis of a pharmacokinetics/ pharmacodynamics study.
    Tominaga N, Kida K, Matsumoto N, Akashi YJ, Miyake F, Kimura K, Shibagaki Y.
    Clin Nephrol; 2015 Jul 27; 84(1):29-38. PubMed ID: 25997504
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Tolvaptan (Otsuka).
    Doggrell SA.
    Curr Opin Investig Drugs; 2004 Sep 27; 5(9):977-83. PubMed ID: 15503654
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Beneficial role of tolvaptan in the control of body fluids without reductions in residual renal function in patients undergoing peritoneal dialysis.
    Mori T, Oba I, Koizumi K, Kodama M, Shimanuki M, Tanno M, Chida M, Saito M, Kiyomoto H, Miyazaki M, Ogawa S, Sato H, Ito S.
    Adv Perit Dial; 2013 Sep 27; 29():33-7. PubMed ID: 24344488
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 60.